Eris Lifesciences Limited has informed the Exchange regarding Board meeting held on May 19, 2025.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts more than Nifty Smallcap 250 and 3.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences' board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Consolidated revenue from operations grew 44% year-on-year to Rs 2,893.64 crore (vs Rs 2,009.15 crore), driven by acquisitions including the Biocon India Branded Formulations business. Standalone net profit, however, fell sharply to Rs 77.39 crore from Rs 299.72 crore, impacted by higher finance costs (Rs 220.24 cr vs Rs 57.42 cr), increased depreciation (Rs 181.77 cr vs Rs 102.39 cr) from intangible assets, and the end of the Section 80IE tax deduction. Operating margin on a standalone basis compressed to 20.04% from 25.98%. The audit reports carry an unmodified (clean) opinion from Deloitte Haskins & Sells LLP. The board also appointed M/s Ravi Kapoor & Associates as Secretarial Auditor for five years (FY26–FY30) and re-appointed M/s Kiran J. Mehta & Co. as Cost Auditor for FY26. Record date for interest payment on two NCD series was set as May 23, 2025.
Strong top-line growth from acquisitions is encouraging, but the steep fall in standalone profit and margin compression signal rising costs and integration challenges. Shareholders should watch for any negative reaction to the sharp PAT decline, though clean audit and long-term growth strategy may provide support.